Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GZR33 and GZR101 in Healthy Men
NCT06556641Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Peptides, Insulin and Analogs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GZR33 and GZR101 in diabetes mellitus (DM) (4 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Area Under the Concentration-Time Curve from 0 to 24 hours and Incidence of Adverse Events. Started Dec 2022; status: completed.
02
Drugs
GZR33GZR101
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06556641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556641.